Related Experiment Video

Updated: Apr 26, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

The potential impact of P53 and APO-1 genetic polymorphisms on hepatitis C genotype 4a susceptibility

Emad F Eskander1, Ahmed A Abd-Rabou1, Mervat S Mohamed2

  • 1Hormones Department, Medical Research Division, National Research Centre, Cairo, Egypt.

Gene
|August 10, 2014
PubMed

Insights

Certain P53 and APO-1 gene variations may indicate susceptibility to Hepatitis C virus (HCV) genotype 4a infection. These genetic markers could aid in identifying individuals at higher risk for HCV genotype 4a.

Area of Science:

  • Virology and Genetics
  • Hepatology
  • Molecular Biology

Background:

  • Hepatitis C virus (HCV) is a global health concern, causing significant morbidity and mortality, particularly cirrhosis.
  • The tumor suppressor gene P53 and apoptotic antigen-1 gene (APO-1) play roles in apoptosis, a mechanism crucial for controlling viral replication.
  • Understanding genetic susceptibility factors is vital for managing HCV, especially genotype 4a, which is prevalent in certain regions.

Purpose of the Study:

  • To investigate the association between P53 72 Arg/Pro and APO-1 -670 A/G polymorphisms and susceptibility to HCV genotype 4a.
  • To evaluate the potential of these genetic variations as biomarkers for HCV genotype 4a infection and disease progression.

Main Methods:

  • Genotyping of P53 (rs 1042522) and APO-1 (rs 1800682) polymorphisms in 160 HCV patients and 80 healthy controls.
  • Quantification of HCV-RNA and assessment of liver fibrotic stages (Metavir scoring) in patient subgroups (F0/1 and F3/4).
  • Statistical analysis of genotype and allele frequencies across different study groups.

Main Results:

  • Significant differences in P53 72 (Pro/Pro, Arg/Arg) and APO-1 -670 (A/A) genotypes were observed between HCV patients and healthy individuals.
  • Distinct P53 and APO-1 genotype distributions were found when comparing mild (F0/1) versus advanced (F3/4) fibrotic stages in HCV patients.
  • P53 (Pro/Pro) and APO-1 (A/A) genotypes showed significant associations with HCV infection and advanced fibrosis.

Conclusions:

  • P53 rs 1042522 (Pro/Pro and Arg/Arg) and APO-1 rs 1800682 (A/A) genotypes are potential genetic markers for HCV genotype 4a susceptibility.
  • These genetic variations may influence disease progression and fibrotic stage development in HCV genotype 4a infected individuals.
  • Further research can explore the clinical utility of these markers in predicting HCV risk and outcomes.

Keywords:
APO-1 −670A/GHCV genotype 4aP53 Arg72ProSNPs

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

8.9K
Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

10.4K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.4K
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
328